使用標靶治療或合併免疫治療之療效及安全性以肝細胞癌及腎細胞癌為例: 統合分析與臨床試驗計畫書
YF Yu - 國立臺灣大學臨床醫學研究所學位論文, 2022 - airitilibrary.com
… carcinoma (HCC) patients and advanced renal cell … Immunotherapy has shown the long-lasting
effects in only a … to improve overall survival (OS) and/or progression-free survival (PFS) in …
effects in only a … to improve overall survival (OS) and/or progression-free survival (PFS) in …
使用標靶治療或合併免疫治療之療效及安全性以肝細胞癌及腎細胞癌為例: 統合分析與臨床試驗計畫書
游雅芳 - 2022 - tdr.lib.ntu.edu.tw
… carcinoma (HCC) patients and advanced renal cell … Immunotherapy has shown the long-lasting
effects in only a … to improve overall survival (OS) and/or progression-free survival (PFS) in …
effects in only a … to improve overall survival (OS) and/or progression-free survival (PFS) in …
胶质瘤免疫治疗新进展
易立， 陶震楠， 杨学军 - 中国肿瘤临床, 2017 - cjco.cn
… Numerous clinical trials have shown that immunotherapy for … vaccines, to provide new ideas
for glioma treatment. … 具有 更长的无进展生存期(progression free survival,PFS)和 更高的放疗…
for glioma treatment. … 具有 更长的无进展生存期(progression free survival,PFS)和 更高的放疗…
药物选择剂量分割顺序对放疗联合免疫治疗晚期非小细胞肺癌疗效的影响
刘仪， 朱宇熹 - 中国肿瘤临床, 2021 - cjco.cn
… have shown that combining immunotherapy with radiotherapy in advanced NSCLC improves
progression-free survival … of immunotherapy combined with radiotherapy in advanced …
progression-free survival … of immunotherapy combined with radiotherapy in advanced …
肾细胞癌免疫治疗的研究进展
Y Kang, LI Youyuan, YU Junfeng, WEI Shaozhong - zlfzyj.com
… investigations have demonstrated that single-agent therapy with … cell immunotherapy (AGS-003)
plus standard treatment in … Overall survival for sorafenib plus interleukin-2 compared …
plus standard treatment in … Overall survival for sorafenib plus interleukin-2 compared …
甲基硫腺苷磷酸化酶在癌轉移與腫瘤進程之抑癌機制
WH Chang - 臺灣大學分子醫學研究所學位論文, 2022 - airitilibrary.com
… -tumor treatment, eg, targeted therapy and immunotherapy. Lung … is associated with worse
overall survival. Despite the above … Taken together, we demonstrate the mechanism of MTAP …
overall survival. Despite the above … Taken together, we demonstrate the mechanism of MTAP …
[HTML][HTML] 放Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent …
B Jia, X Zhao, D Wu, Z Dong, Y Chi, J Zhao… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
… -TKI) and immunotherapy have developed rapidly in recent … response rate and longer
progression-free survival (PFS) in … FCN2 and MAN1C1 examined in our study have been shown …
progression-free survival (PFS) in … FCN2 and MAN1C1 examined in our study have been shown …
[HTML][HTML] 肾细胞癌免疫治疗的研究进展
杨康， 李有元， 喻俊峰， 魏少忠 - 肿瘤防治研究, 2015 - zlfzyj.com
… Immunotherapy is initially intended to activate the immune … investigations have demonstrated
that single-agent therapy … , mRCC),中位总生存期(overall survival, OS)少于2年 [1, 2] .1995…
that single-agent therapy … , mRCC),中位总生存期(overall survival, OS)少于2年 [1, 2] .1995…
犬癌症之免疫治療與影像診斷
TF Chuang - 臺灣大學獸醫學研究所學位論文, 2011 - airitilibrary.com
… achievement in targeted therapy and immunotherapy, we … The vaccine significantly improved
the overall survival time in the CT … of therapy in canines cancers and has shown promising …
the overall survival time in the CT … of therapy in canines cancers and has shown promising …
[HTML][HTML] PD-1/PD-L1 调控及其在肿瘤靶向治疗的前景展望
倪杰明， 倪安平 - Chinese Medical Sciences Journal, 2018 - cmsj.cams.cn
… -L1 axis can be treated as a target for tumor immunotherapy, and … overall survival of 63
patients with renal clear cell carcinoma … Given the fact that BET inhibitors have been proven to be …
patients with renal clear cell carcinoma … Given the fact that BET inhibitors have been proven to be …